Emmes Group, a leading global contract research organization (CRO), has announced a multi-year strategic partnership with Miimansa AI on July 23, 2024. This partnership aims to revolutionize clinical research at Emmes by acquiring Miimansa's Clinical Entity Modeling tools based on advanced large language modeling (LLM) techniques and generative AI. Artificial intelligence (AI) has the potential to transform healthcare, including clinical research. Emmes Group is further developing its technology platform, Veridix AI, and Miimansa's Clinical Entity Modeling technology will play a crucial role in accelerating the development of automated text processing solutions customized for clinical research. The partnership will focus on improving the processing of large amounts of clinical data and enabling text to text transformations such as protocol authoring and medical writing. This will reduce the time and costs associated with manual data handling and analysis. "We are thrilled to collaborate with Miimansa AI to bring state-of-the-art AI technology to the forefront of clinical research, " said Sastry Chilukuri, CEO of Emmes Group. "The clinical entity modeling tools obtained through this partnership will expedite the development and implementation of Emmes Group's Gen AI platform, Concord, thereby enabling faster, better, and more efficient clinical trials. " Dr. Vibhu Agarwal, founder and CEO of Miimansa AI, added, "Partnering with Emmes Group is a significant milestone for us. Their expertise and comprehensive clinical trial data provide a unique opportunity to apply our advanced AI techniques in real-world scenarios.

Together, we aim to transform the landscape of clinical research, making it faster, more cost-effective, and ultimately more successful in delivering safe and effective treatments. " About Emmes Group: Emmes Group is a privately held contract research organization (CRO) owned by New Mountain Capital (https://www. newmountaincapital. com). With over 47 years of experience, Emmes Group started as Emmes and became one of the primary clinical research providers to the US government. Since then, it has expanded into public-private partnerships and commercial biopharma, specializing in cell and gene therapy, vaccines and infectious diseases, ophthalmology, rare diseases, and neuroscience. Today, Emmes Group is transforming the future of clinical research by creating the industry's first native digital and AI-based CRO optimized for faster, better, and more efficient programs, where human intelligence meets artificial intelligence. About Miimansa AI: Miimansa AI is a health tech startup at the forefront of AI and machine learning applications in life sciences and healthcare. Led by former faculty and alumni from IIT Kanpur and Stanford University, Miimansa AI specializes in clinical data management and biomedical research. The company develops innovative solutions that leverage large language models to automate and enhance various aspects of clinical research. Logo - https://mma. prnewswire. com/media/220594/Emmes_Group_Logo. jpg